Celltrion Healthcare - Articles and news items

Why biosimilars are changing the pharmaceutical industry

Blog, Z Homepage promo / 26 May 2017 / Ho-ung Kim, Head of Strategy and Operations Division for Celltrion Healthcare

We caught up with Celltrion Healthcare’s Ho-ung Kim to find out how biosimilars cut costs, increase access to medicine and are ultimately changing the industry…

First biosimilar mAb in oncology granted EU approval

Industry news / 23 February 2017 / Niamh Marriott, Digital Editor

The European Commission has approved Truxima (biosimilar rituximab) for all indications of reference rituximab in the European Union (EU)…

Crohn’s disease

Celltrion Healthcare & Pfizer’s biosimilar shows positive results in Crohn’s disease study

Industry news / 20 February 2017 / Niamh Marriott, Digital Editor

Celltrion Healthcare presented the primary outcome from its pivotal randomised controlled trial of CT-P13 (biosimilar infliximab) in Crohn’s disease.

Celltrion Healthcare on Remsima and biosimilars

Blog, Z Homepage promo / 15 July 2016 / European Pharmaceutical Review

With Remsima being on the market for a year, European Pharmaceutical Review caught up with Celltrion Healthcare to find out more about biosimilars…

Celltrion to develop assay for evidence-based decision-making in anti-TNF treatment

Industry news / 5 July 2016 / Victoria White, Digital Content Producer

Celltrion is to develop laboratory tests that will enable physicians to identify when patients on an anti-TNF drug require a change of dose…

FDA approves Inflectra (biosimilar infliximab) in the US

Industry news / 6 April 2016 / Victoria White, Digital Content Producer

With this approval, Celltrion’s Inflectra becomes the first biosimilar monoclonal antibody (mAb) medication to receive approval in the US…

No difference in efficacy or immunogenicity following switch to biosimilar Remsima

Industry news / 28 October 2015 / Victoria White

New clinical data indicate no differences in efficacy, adverse events and immunogenicity when patients with inflammatory bowel disease are switched to biosimilar infliximab Remsima from originator infliximab…

Data for Celltrion’s biosimilar infliximab CT-P13 presented at EULAR 2015

Industry news / 10 June 2015 / Victoria White

Data presented at EULAR 2015 show that the effectiveness of Celltrion’s biosimilar infliximab was similar to the RMP in rheumatoid arthritis…

Experts share real-world experience with biosimilar infliximab in patients with inflammatory bowel disease

Industry news / 19 May 2015 / Victoria White

Clinical experience of biosimilar infliximab shows that the treatment is comparable to the reference medicinal product in terms of efficacy and safety…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...